Advanced search
Publication Cover
Pharmacogenomics Volume 8, 2007 - Issue 3
Submit an article Journal homepage
445
Views
0
CrossRef citations to date
0
Altmetric
Research Report

Warfarin and Cytochrome P450 2C9 Genotype: Possible Ethnic Variation in Warfarin Sensitivity

Carmel Kealey1 University of Pennsylvania, Department of Pharmacology and Center for Pharmacogenetics, School of Medicine, Philadelphia, PA, USA
,
Zhen Chen2 University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, School of Medicine, Philadelphia, PA, USA
,
Jason Christie2 University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, School of Medicine, Philadelphia, PA, USA;3 University of Pennsylvania, Department of Medicine, Cardiovascular Medicine Division, School of Medicine, Philadelphia, PA, USA
,
Caroline F Thorn1 University of Pennsylvania, Department of Pharmacology and Center for Pharmacogenetics, School of Medicine, Philadelphia, PA, USA
,
Alexander S Whitehead1 University of Pennsylvania, Department of Pharmacology and Center for Pharmacogenetics, School of Medicine, Philadelphia, PA, USA
,
Maureen Price2 University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, School of Medicine, Philadelphia, PA, USA
,
Frederick F Samaha3 University of Pennsylvania, Department of Medicine, Cardiovascular Medicine Division, School of Medicine, Philadelphia, PA, USA;4 Veterans Affairs Medical Center, University and Woodlands Avenues, Philadelphia, PA, USA
&
Stephen E Kimmel2 University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, School of Medicine, Philadelphia, PA, USA;3 University of Pennsylvania, Department of Medicine, Cardiovascular Medicine Division, School of Medicine, Philadelphia, PA, USA
 show all
Pages 217-225 | Published online: 27 Feb 2007

Bibliography

  • Adcock DM , KoftanC, CrisanD, Kiechle FL: Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Arch. Pathol. Lab. Med.128(12) , 1360–1363 (2004).
  • Douketis JD , LaneA, MilneJ, GinsbergJS: Accuracy of a portable international normalization ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement.Thromb. Res.92(1) , 11–17 (1998).
  • Beyth RJ : Management of haemorrhagic complications associated with oral anticoagulant treatment.Expert Opin. Drug Saf.1(2) , 129–136 (2002).
  • Ansell J , HirshJ, DalenJ et al.: Managing oral anticoagulant therapy. Chest119(Suppl. 1) , S22–S38 (2001).
  • Wadelius M , SorlinK, WallermanO et al.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J.4(1) , 40–48 (2004).
  • Hirsh J , DalenJE, DeykinD, PollerL: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.Chest102(Suppl. 4) , S312–S326 (1992).
  • Haber LT , MaierA, GentryPR, ClewellHJ, DoursonML: Genetic polymorphisms in assessing interindividual variability in delivered dose.Regul. Toxicol. Pharmacol.35(2 Pt 1) , 177–197 (2002).
  • Kaminsky LS , ZhangZY: Human P450 metabolism of warfarin.Pharmacol. Ther.73(1) , 67–74 (1997).
  • Kirchheiner J , BrockmollerJ: Clinical consequences of cytochrome P450 2C9 polymorphisms.Clin. Pharmacol. Ther.77(1) , 1–16 (2005).
  • Haining RL , HunterAP, VeroneseME, TragerWF, RettieAE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.Arch. Biochem. Biophys.333(2) , 447–458 (1996).
  • Sullivan-Klose TH , GhanayemBI, BellDA et al.: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics6(4) , 341–349 (1996).
  • Kaminsky LS , de Morais SM, Faletto MB, Dunbar DA, Goldstein JA: Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol.43(2) , 234–239 (1993).
  • Crespi CL , MillerVP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase.Pharmacogenetics7(3) , 203–210 (1997).
  • Margaglione M , ColaizzoD, D‘AndreaG et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost.84(5) , 775–778 (2000).
  • Aithal GP , DayCP, KestevenPJ, DalyAK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet353(9154) , 717–719 (1999).
  • Tabrizi AR , ZehnbauerBA, BoreckiIB, McGrathSD, BuchmanTG, FreemanBD: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.J. Am. Coll. Surg.194(3) , 267–273 (2002).
  • Taube J , HalsallD, BaglinT: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.Blood96(5) , 1816–1819 (2000).
  • Gage BF , EbyC, MilliganPE, BanetGA, DuncanJR, McLeodHL: Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.Thromb. Haemost.91(1) , 87–94 (2004).
  • Rieder MJ , ReinerAP, GageBF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med.352(22) , 2285–2293 (2005).
  • Walker AH , NajarianD, WhiteDL, Jaffe JF, Kanetsky PA, Rebbeck TR: Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. Environ. Health Perspect.107(7) , 517–520 (1999).
  • Barbaux S , KluijtmansLA, Whitehead AS: Accurate and rapid ‘multiplex heteroduplexing‘ method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin. Chem.46(7) , 907–912 (2000).
  • Yasar U , EliassonE, DahlML, Johansson I, Ingelman-Sundberg M, Sjoqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun.254(3) , 628–631 (1999).
  • Higashi MK , VeenstraDL, KondoLM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA287(13) , 1690–1698 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.